Pregabalin Capsule
Product Images NDC 63629-8208

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8208). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298208)

Label for Pregabalin Capsules, USP 200 mg by Bryant Ranch Prepack. The label indicates 30 capsules per package and includes storage instructions (20° to 25° C, with excursions allowed 15° to 30° C). It features the NDC 63629-8208-01 and the BRP Pharmaceuticals logo.*

FDA Label Image

Label (Lbl6362982082)

Pregabalin 200 mg Capsule label by Bryant Ranch Prepack. The label states the capsule is an orange capsule with a reference to Lyrica 200 mg capsules by ScieGen Pharmaceuticals Inc. It includes storage instructions to keep at room temperature (20°-25°C) and a warning to keep drugs out of reach of children. The package contains 30 capsules with NDC 63629-8208-1 and mentions prescription use only.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at different doses (25 mg, 100 mg, 200 mg three times a day) and placebo. The x-axis represents percent improvement in pain from baseline, and the y-axis represents the percent of patients improved. Lines for each dose show varying levels of patient improvement compared to placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day to placebo. Two lines represent patient responses, with Pregabalin showing higher improvement rates across pain reduction percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. The graph compares patients taking Pregabalin at doses of 75 mg, 150 mg, and 300 mg twice a day versus a placebo group, depicting the percentage of patients with pain improvement at various levels.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

Line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph plots pain improvement percentages along the x-axis from 0 to 100, with the y-axis showing the percent of patients improved.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It includes three lines comparing Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents percent of patients improved (0 to 100%). Vertical lines mark 30% and 50% improvement thresholds.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart displaying responder rates (%) in two clinical studies labeled Study E1 and Study E3. The x-axis shows treatment groups including placebo and various daily dosages of Pregabalin (50 mg, 150 mg, 300 mg, 600 mg) with BID or TID dosing frequency. The y-axis represents responder rates from 0% to 60%. Bars indicate increasing responder rates with higher Pregabalin doses, with asterisked bars denoting statistically significant differences from placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction (median % change from baseline) on the vertical axis versus dose (mg/day) on the horizontal axis. Four study groups are represented: Study E1 BD, Study E2 TID, Study E3 BD, and Study E3 TID with data points indicating significant p-values. The graph compares seizure reduction effects across different doses and dosing schedules, including a placebo dose at zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 800 mg daily dose, Pregabalin 450 mg daily dose, Pregabalin 300 mg daily dose, and placebo, with separate lines for each group illustrating patient improvement over increasing pain relief percentages.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing the estimated percentage of subjects without LTR (y-axis) over a period of days up to 180 (x-axis) between two groups: Pregabalin (solid line) and Placebo (dashed line). The Pregabalin group consistently shows a higher percentage of subjects without LTR compared to the Placebo group throughout the duration.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over baseline to week 12 BOCF between Pregabalin and placebo groups. The solid line represents Pregabalin with a higher percentage of subjects improved across various improvement thresholds, while the dotted line represents the placebo group with lower improvement percentages.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percent of subjects improved between Pregabalin and placebo groups. The x-axis represents the percent improved from baseline to week 16 BOCF, ranging from 0 to 100, while the y-axis shows the percent of subjects improved. The solid line indicates Pregabalin consistently has a higher percentage of subjects improved compared to the placebo, represented by the dashed line.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine levels, with an adjustment factor for female patients. This panel provides the mathematical expression using variables for age in years, weight in kilograms, and serum creatinine in mg/dL.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin showing its molecular arrangement with labeled functional groups, including a carboxylic acid (CO2H) and an amino group (NH2).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.